Amarin | AMRN - Operating Profit


Amarin reported $-1.7M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.5B 363M Sep/2025